| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6182792 | Gynecologic Oncology | 2014 | 5 Pages |
Abstract
Rilotumumab was well-tolerated, but had limited activity. The level of activity does not warrant further evaluation of rilotumumab as a single agent in patients with ovarian cancer.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Lainie P. Martin, Michael Sill, Mark S. Shahin, Matthew Powell, Paul DiSilvestro, Lisa M. Landrum, Stephanie L. Gaillard, Michael J. Goodheart, James Hoffman, Russell J. Schilder,